Dyslipidaemia and its management after immunosuppressive treatment;Mécanismes des hyperlipidémies dues aux immunosuppresseurs

Therapie

Volumn 59, Issue 4, 2004, Pages 463-469

  Gueguen, Yann ^a   Ferrari, Luc ^a   Batt, Anne Marie ^a  

^a INSERM   (France)

Author keywords

Apolipoproteins; Bile acid; Hypercholesterolaemia; Hypertriglyceridaemia; Immunosuppressive drugs

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN B100; APOLIPOPROTEIN C2; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; BILE ACID; CHOLESTEROL; CHOLESTEROL 7ALPHA MONOOXYGENASE; CYCLOSPORIN A; CYTOCHROME P450 27A1; CYTOCHROME P450 7B1; CYTOCHROME P450 8B1; CYTOCHROME P450 ISOENZYME; EVEROLIMUS; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; IMMUNOSUPPRESSIVE AGENT; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; RAPAMYCIN; TACROLIMUS; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

BILE ACID METABOLISM; BILE SECRETION; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; CONFERENCE PAPER; DYSLIPIDEMIA; ENZYME ACTIVITY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

EID: 8444219691     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: 10.2515/therapie:2004078     Document Type: Conference Paper

References (61)

1. Kasiske BL, Tortoriee KL, Heim-Duthoy KL, et al. The adverse impact of cyclosporine on serum lipids in renal transplant recipients. Am J Kidney Dis 1991; 17: 700-7
2. Ichimaru N, Takahara S, Kokado Y, et al. Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus. Atherosclerosis 2001; 158: 417-23
3. Taylor DO, Barr ML, Meiser BM, et al. Suggested guidelines for the use of tacrolimus in cardiac transplant recipients. J Heart Lung Transplant 2001; 20: 734-8
4. Groth CG. Rapport européen public d'évaluation (EPAR) du comité des spécialités pharmaceutiques. Rapamune. The European Agency for the evaluation of Medicinal products 2001, CPMP/4206/00
5. Morrisett JD, Abdel-Fattah G, Hoogeveen R, et al. Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. J Lipid Res 2002; 43: 1170-80
6. Kovarik JM, Kaplan B, Tedesco Suva H, et al. Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range. Transplantation 2002; 73: 920-5
7. Ballantyne CM, Podet EJ, Patsch WP, et al. Effects of cyclosporine therapy on plasma lipoprotein levels. JAMA 1989; 262: 53-6
8. McCune TR, Thacker II LR, Peters TG, et al. Effects of tacrolimus on hyperlipidemia after successful renal transplantation: a Southeastern Organ Procurement Foundation multicenter clinical study. Transplantation 1998; 65: 87-92
9. Boots JM, van Duijnhoven EM, Christians MH, et al. Single-center experience with tacrolimus versus cyclosporine-Neoral in renal transplant recipients. Transpl Int 2001; 14; 370-83
10. Saunders RN, Metcalfe MS, Nicholson M. Rapamycin in transplantation: a review of the evidence. Kidney Int 2001; 59: 3-16
11. Blum CB. Effects of sirolimus on lipids in renal allograft recipients: an analysis using the Framingham risk model. Am J Transplant 2002; 2: 551-9
12. Hoogeveen RC, Ballantyne CM, Pownall HJ, et al. Effect of sirolimus on the metabolism of apoB100-containing lipoproteins in renal transplant patients. Transplantation 2001; 72: 1244-50
13. Kahan BD, Podbielski J, Napoli KL, et al. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation. Transplantation 1998; 66: 1040-6
14. McAlister VC, Gao Z, Peltekian K, et al. Sirolimus-tacrolimus combination immunosuppression. Lancet 2000; 355: 376-7
15. Moore R, Hernandez D, Valantine H. Calcineurin inhibitors and post-transplant hyperlipidaemias. Drug Saf 2001; 24: 755-66
16. Tur MD, Garrigue V, Vela C, et al. Apolipoprotein CIII is upregulated by anticalcineurins and rapamycin: implications in transplantation-induced dyslipidemia. Transplant Proc 2000; 32: 2783-4
17. Gonzalez-Amieva A, Lopez-Miranda J, Fuentes F. et al. Genetic variations of the apolipoprotein E gene determine the plasma triglyceride levels after heart transplantation. J Heart Lung Transplant 2000; 19: 765-70
18. Massy ZA, De Bandt JP, Morelon E, et al. Hyperlipidemia and post-heparin lipase activities in renal transplant recipients treated with sirolimus or cyclosporin A [letter]. Nephrol Dial Transplant 2000; 15: 928
19. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986; 232: 34-47
20. Nimpf J, Schneider WJ. From cholesterol transport to signal transduction: low density lipoprotein receptor, very low density lipoprotein receptor, and apolipoprotein E receptor-2. Biochim Biophys Acta 2000: 1529: 287-98
21. Luoma J, Hiltunen T, Sarkioja T, et al. Expression of alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein and scavenger receptor in human atherosclerotic lesions. J Clin Invest 1994; 93: 2014-21
22. Hiltunen TP, Yla-Herttuala S. Expression of lipoprotein receptors in atherosclerotic lesions. Atherosclerosis 1998; 137: S81-8
23. Winegar DA, Salisbury JA, Sundseth SS, et al. Effects of cyclosporine on cholesterol 27-hydroxylation and LDL receptor activity in HepG2 cells. J Lipid Res 1996; 37: 179-91
24. Rayyes OA, Wallmark A, Floren CH. Cyclosporine inhibits catabolism of low-density lipoproteins in HepG2 cells by about 25%. Hepatology 1996; 24: 613-9
25. Rubin EM, Krauss RM, Spangler EA, et al. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature 1991; 353: 265-7
26. Claudel T, Sturm E, Duez H, et al. Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element. J Clin Invest 2002; 109: 961-71
27. Andany MA, Kasiske BL. Dyslipidemia and its management after renal transplantation. J Nephrol 2001 : 14: 581-8
28. Souidi M, Parquet M, Dubrac S, et al. New bile acid biosynthesis pathways. Gastroenterol Clin Biol 2001; 25: 81-92
29. Princen HMG, Post SM, Twisk Y. Regulation of bile acid biosynthesis. Curr Pharm Des 1997; 3: 59-84
30. Cohen JC, Cali JJ, Jelinek DF, et al. Cloning of the human cholesterol 7 alpha-hydroxylase gene (CYP7) and localization to chromosome 8q11-q12. Genomics 1992; 14: 153-61
31. Erlinger S. How is a cholesterol gallstone formed? Gastroenterol Clin Biol 1994; 18: 984-7
32. Ishibashi S, Schwarz M, Frykman PK, et al. Disruption of cholesterol 7alpha-hydroxylase gene in mice. I. Postnatal lethality reversed by bile acid and vitamin supplementation. J Biol Chem 1996; 271: 18017-23
33. Princen HMG, Meijer P, Wolthers BG, et al. Cyclosporin A blocks bile acid synthesis in cultured hepatocytes by specific inhibition of chenodeoxycholic acid synthesis. Biochem J 1991; 275: 501-5
34. Vlahcevic ZR, Stravitz RT, Heuman DM, et al. Quantitative estimations of the contribution of different bile acid pathways to total bile acid synthesis in the rat. Gastroenterology 1997; 113: 1949-57
35. Anderson S, Davis DL, Dahlback H, et al. Cloning, structure, and expression of the mitochondrial cytochrome P-450 sterol 26-hydroxylase, a bile acid biosynthetic enzyme. J Biol Chem 1989; 264; 8222-9
36. Crisby M, Nilsson J, Kostulas V, et al. Localization of sterol 27-hydroxylase immuno-reactivity in human atherosclerotic plaques. Biochim Biophys Acta 1997; 1344: 278-85
37. Rennert H, Fischer RT, Alvarez JG, et al. Generation of regulatory oxysterols: 26-hydroxylation of cholesterol by ovarian mitochondria. Endocrinology 1990; 127: 738-46
38. Reiss AB, Martin KO, Rojer DE. et al. Sterol 27-hydroxylase: expression in human arterial endothelium. J Lipid Res 1997; 38 (6): 1254-60
39. Sälen G, Berginer V, Shore V. et al. Increased concentrations of cholestanol and apolipoprotein B in the cerebrospinal fluid of patients with cerebrotendinous xanthomatosis: effect of chenodeoxycholic acid. N Engl J Med 1987; 316: 1233-8
40. Esterman AL, Baum H, Javitt NB, et al. 26-hydroxycholesterol: regulation of hydroxymethylglutaryl-CoA reductase activity in Chinese hamster ovary cell culture. J Lipid Res 1983; 24: 1304-9
41. Souidi M, Parquet M, Ferezou J, et al. Modulation of cholesterol 7 alpha-hydroxylase and sterol 27-hydroxylase activities by steroids and physiological conditions in hamster. Life Sci 1999; 64: 1585-93
42. Axelson M, Larsson O. Low density lipoprotein (LDL) cholesterol is converted to 27-hydroxycholesterol in human fibroblasts: evidence that 27-hydroxycholesterol can be an important intracellular mediator between LDL and the suppression of cholesterol production. J Biol Chem 1995; 270: 15102-10
43. Javitt NB. Bile acid synthesis from cholesterol: regulatory and auxiliary pathways. FASEB J 1994; 8: 1308-11
44. Diczfalusy U, Lund E, Lutjohann D, et al. Novel pathways for elimination of cholesterol by extrahepatic formation of side-chain oxidized oxysterols. Scand J Clin Lab Invest Suppl 1996; 226: 9-17
45. Mizuta K, Kobayashi E, Uchida H, et al. Cyclosporine inhibits transport of bile acid in rats: comparison of bile acid composition between liver and bile. Transplant Proc 1999; 31: 2755-6
46. Chiang JYL. Regulation of bile acid synthesis. Front Biosci 1998; 3: D176-93
47. Souidi M, Parquet M, Dubrac S. et al. Assay of microsomal oxysterol 7alpha-hydroxylase activity in the hamster liver by a sensitive method: in vitro modulation by oxysterols. Biochim Biophys Acta 2000; 1487: 74-81
48. Deters M, Nolle K, Kirchner G, et al. Comparative study analyzing effects of sirolimus-cyclosporine and sirolimus-tacrolimus combinations on bile flow in the rat. Dig Dis Sci 2001; 40: 2120-6
49. Deters M, Klabunde T, Kirchner G, et al. Sirolimus/cyclosporine/ tacrolimus interactions on bile flow and biliary excretion of immunosuppressants in a subchronic bile fistula rat model. Br J Pharmacol 2002; 136: 604-12
50. Bramow S, Ott P, Thomsen Nielsen F, et al. Cholestasis and regulation of genes related to drug metabolism and biliary transport in rat liver following treatment with cyclosporine A and sirolimus (rapamycin). Pharmacol Toxicol 2001; 89: 133-9
51. Kast HR, Goodwin B, Tarr PT, et al. Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J Biol Chem 2002; 277: 2908-15
52. Kast HR, Nguyen CM, Sinal CJ, et al. Farnesoid X-activated receptor induces apolipoprotein C-II transcription: a molecular mechanism linking plasma triglyceride levels to bile acids. Mol Endocrinol 2001; 15: 1720-8
53. Sinai CJ, Tonkin M, Miyata M, et al. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 2000; 102: 731-44
54. Maloney PR, Parks DJ, Haffner CD, et al. Identification of a chemical tool for the orphan nuclear receptor FXR. J Med Chem 2000; 43: 2971-4
55. Bauchat D, Gruffat D, Graulet B, et al. Production et stockage des triglycérides par le foie. Cah Nutr Diét 1997; 32: 233-40
56. Ghiselli G, Gregg RE, Zech LA, et al. Phenotype study of apolipoprotein E isoforms in hyperlipoproteinaemic patients. Lancet 1982; II: 405-7
57. Ito Y, Azrolan N, O'Connell A, et al. Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice. Science 1990; 249: 790-3
58. Benlian P, de Gennes JL, Dairou F, et al. Phenotypic expression in double heterozygotes for familial hypercholesterolemia and familial defective apolipoprotein B-100. Hum Mutat 1996; 7: 340-5
59. Schultz JR, Tu H, Luk A, et al. Role of LXRs in control of lipogenesis. Genes Dev 2000; 14: 2831-8
60. Repa JJ, Lund EG, Horton JD, et al. Disruption of the sterol 27-hydroxylase gene in mice results in hepatomegaly and hypertriglyceridemia: reversal by cholic acid feeding. J Biol Chem 2000; 275: 39685-92
61. Vaziri ND, Liang K, Azad H. Effect of cyclosporine on HMG-CoA reductase, cholesterol 7alpha-hydroxylase, LDL receptor, HDL receptor, VLDL receptor, and lipoprotein lipase expressions. J Pharmacol Exp Ther 2000; 294: 778-83